The Incretin Mimetic Exenatide as a Monotherapy in Patients with Type 2 Diabetes
Author:
Affiliation:
1. Amylin Pharmaceuticals Inc., San Diego, California.
Publisher
Mary Ann Liebert Inc
Subject
Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism
Link
http://www.liebertpub.com/doi/pdf/10.1089/dia.2006.0024
Reference35 articles.
1. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.
2. Development of Glucagon-Like Peptide-1-Based Pharmaceuticals as Therapeutic Agents for the Treatment of Diabetes
3. Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus
4. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1
5. Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An Assessment of Retinopathy in Type-II Diabetics along with Microalbuminuria;Pakistan Journal of Medical and Health Sciences;2021-07-26
2. Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes;Current Pharmaceutical Design;2021-04-08
3. Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial;Metabolism;2018-08
4. GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2016-08
5. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials;International Journal of Clinical Practice;2016-07-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3